Health ministry rules out any immediate action against controversial anti-diabetic drug rosiglitazone
Health ministry rules out any immediate action against controversial anti-diabetic drug rosiglitazone
The drug control authorities in India have clarified that there is no immediate plan to ban the controversial anti-diabetic drug rosiglitazone in India in the wake of recent observations by the US FDA. Senior health ministry officials said that the ministry will wait for the decision of the DTAB in this regard before taking any action.
Read more on PharmaBiz
Related posts:
- What can a type-1 diabetic do for short term health insurance?
- Vital Mineral Supplements for Diabetic Health
- Canadians tell me about your health care. My daughter is a type one insulin dependent diabetic.?
- Accu-Chek Aviva Diabetic Monitoring Kit - Meter Program
- Clinical trial for diabetic macular edema enrolling patients